

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. 074973.0117	Serial No. 09/754,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant David J. Grainger	
		Filing Date January 4, 2001	Group 1617
		Examiner Kim, Jennifer M.	

PTO-1449 (Rev. 2-82)

FEB 16 2006

U.S. PATENT AND TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

*Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.		Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
Z	1	Wärri, Anni, Toremifene-Induced Regression in Breast Cancer, 1993, pp. 1-76 and references I-V.
	2	Wärri, Anni and Harkonen, P., Indirect Regulation Of erbB2 Expression by Antiestrogen in Human Breast Cancer Cells, 1993, pp. 1-12.
	3	Wärri, Anni, Isola, Harkonen, Estrogen and antiestrogen regulation of amplified erbB2 gene expression and ectodomain shedding in BT-474 human breast cancer cells, 1993, pp. 1-24.
Z	4	Wärri, Anni et al., Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro, J Natl Cancer Inst. 1993 Sep 1;85(17):1412-8.

NY02:540270.1

Examiner

Date Considered

4/24/06

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. 074973.0117	Serial No. 09/754,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant David J. Grainger	
		Filing Date January 4, 2001	Group 1617
		Examiner Kim, Jennifer M.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
✓	5	Sawada et al., Fifty-Two Week Oral Toxicity Study and Recovery Study of Toremifene Citrate (NK622) in Female Rats, 1992, Pharmacometrics [Oyo yakuri], Vol. 44, pp. 357-373. (with translation from Japanese pp. 1-16)	
	6	Wärri AM, Laine AM, Majasuo KE, Alitalo KK, Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer. 1991 Oct 21;49(4):616-23.	
✓	7	Vuorio T, Warri A, Sandberg M, Alitalo K, Vuorio E. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. Int J Cancer. 1988 Nov 15;42(5):774-9.	

NY02:540270.1	Examiner	Date Considered
---------------	----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.